News

NeuroRx, Inc., a clinical stage biopharma company focused on development of drugs targeting depression and suicidality, announced that it has initiated a pivotal Phase 2b/3 study for…
Read More...

Altimmune, Inc. announced that it has entered into an agreement to acquire Spitfire Pharma, Inc. (Spitfire) including its product candidate SP-1373 (to be renamed ALT-801), a potent…
Read More...

ImaginAb Inc., a clinical stage immuno-oncology imaging company, announced that it has entered into a non-exclusive license and collaboration agreement with Roche. Under the terms of…
Read More...

Mirati Therapeutics, Inc. announced a clinical collaboration agreement with Novartis to evaluate the combination of MRTX849, Mirati's investigational KRAS G12C inhibitor and TNO155,…
Read More...

Lyndra Therapeutics, the company making daily pills a thing of the past, has announced a partnership with Gilead Sciences, Inc. to develop and commercialize ultra-long-acting oral HIV…
Read More...

SunGen Pharma announced it has received its sixth ANDA approval from the US Food and Drug Administration (FDA). The sixth approved ANDA is for Methylprednisolone tablets, 4 mg. This…
Read More...

Ligand Pharmaceuticals Incorporated and SQ Innovation AG announced that the two companies have entered into long-term, exclusive commercial license and supply agreements for use of…
Read More...

BeiGene, Ltd. announced that the China National Medical Products Administration (NMPA, formerly known as the CFDA) has granted priority review status to the supplemental new drug…
Read More...

Grifols announced that Xembify, its new 20% subcutaneous immunoglobulin, has been approved by the U.S. Food and Drug Administration (FDA). Xembify is used to treat primary…
Read More...

Confo Therapeutics, an emerging drug discovery company, and DyNAbind GmbH announce a drug discovery collaboration on an undisclosed G-protein coupled receptor (GPCR). The…
Read More...

Roche announced that the phase III MINISTONE-2 study met its primary endpoint, demonstrating that Xofluza (baloxavir marboxil) was well tolerated in children with flu. The study also…
Read More...

GSK announced the start of a phase III clinical development programme with otilimab, an investigational anti-granulocyte macrophage colony-stimulating factor (anti GM-CSF) monoclonal…
Read More...

Telix Pharmaceuticals Limited, a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or…
Read More...

China SXT Pharmaceuticals, a specialty pharmaceutical company focusing on the research, development, manufacture, marketing and sales of Traditional Chinese Medicine Pieces, announced…
Read More...

ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, announced that the European Commission has…
Read More...

Today, the U.S. Food and Drug Administration granted accelerated approval to Xpovio (selinexor) tablets in combination with the corticosteroid dexamethasone for the treatment of adult…
Read More...

LEO Pharma and Bayer announced the achievement of the relevant closing conditions to allow the transfer of Bayer’s global prescription dermatology business to LEO Pharma. The companies…
Read More...

Appili Therapeutics Inc. announced that the United States Department of Defense, (DOD) Congressionally Directed Medical Research Programs, Peer Reviewed Medical Research Program (PRMRP)…
Read More...

Incyte and Zai Lab Ltd. announced that the companies have entered into a collaboration and license agreement for the development and commercialization of INCMGA0012, an investigational…
Read More...

Amicus Therapeutics, Inc. has entered into a strategic manufacturing agreement with Paragon Gene Therapy, a unit of Catalent Biologics, for clinical manufacturing capabilities and…
Read More...